NEW YORK (GenomeWeb) – GenMark Diagnostics reported after the close of the market on Monday that its third quarter revenues rose 36 percent year over year, driven in part by ePlex analyzer placements.
For the three months ended Sept. 30, the firm reported revenues of $15.8 million, up from $11.6 million a year ago, and beating the consensus Wall Street estimate of $15.5 million.